Prudential PLC Lowers Holdings in United Therapeutics Corporation $UTHR

Prudential PLC decreased its holdings in United Therapeutics Corporation (NASDAQ:UTHR) by 75.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,472 shares of the biotechnology company’s stock after selling 4,636 shares during the quarter. Prudential PLC’s holdings in United Therapeutics were worth $717,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Torren Management LLC purchased a new position in shares of United Therapeutics in the fourth quarter valued at approximately $26,000. Activest Wealth Management lifted its stake in United Therapeutics by 1,400.0% in the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 56 shares during the last quarter. WealthCollab LLC lifted its stake in United Therapeutics by 55.9% in the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 38 shares during the last quarter. Rakuten Securities Inc. lifted its stake in United Therapeutics by 76.7% in the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 46 shares during the last quarter. Finally, Entrust Financial LLC purchased a new position in United Therapeutics in the fourth quarter worth approximately $31,000. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently issued reports on UTHR shares. Oppenheimer lifted their price target on shares of United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research note on Thursday, February 26th. Morgan Stanley set a $516.00 price target on shares of United Therapeutics in a research note on Thursday, May 7th. TD Cowen reiterated a “buy” rating on shares of United Therapeutics in a research note on Thursday, May 21st. Cantor Fitzgerald lifted their price target on shares of United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a research note on Thursday, March 12th. Finally, Wells Fargo & Company upgraded shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their price target for the stock from $575.00 to $735.00 in a research note on Thursday, May 7th. Eleven equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $619.42.

Insider Transactions at United Therapeutics

In other United Therapeutics news, CFO James Edgemond sold 10,000 shares of the business’s stock in a transaction on Monday, March 23rd. The shares were sold at an average price of $527.48, for a total transaction of $5,274,800.00. Following the sale, the chief financial officer directly owned 18,876 shares in the company, valued at approximately $9,956,712.48. The trade was a 34.63% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold a total of 624,043 shares of company stock valued at $351,930,785 in the last three months. Corporate insiders own 8.60% of the company’s stock.

United Therapeutics Trading Down 0.9%

United Therapeutics stock opened at $544.69 on Tuesday. United Therapeutics Corporation has a twelve month low of $272.12 and a twelve month high of $609.35. The stock has a 50 day moving average of $568.47 and a two-hundred day moving average of $519.64. The stock has a market capitalization of $23.12 billion, a price-to-earnings ratio of 20.11, a PEG ratio of 1.79 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The business had revenue of $781.50 million for the quarter, compared to analysts’ expectations of $797.40 million. During the same period last year, the company posted $6.63 earnings per share. The business’s quarterly revenue was down 1.6% on a year-over-year basis. Equities analysts predict that United Therapeutics Corporation will post 26.84 earnings per share for the current year.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.